Polpharma Biologics, European Biotechnology Company, Selects Box for Cloud Content Management
“Polpharma Biologics develops biosimilar drugs to increase access for patients to much needed therapies. As a biotech company, we know how crucial it is to maintain quality across every field and daily activity,” said
“Polpharma Biologics is one of the most modern biotech development and production companies in Europe,” said Michael Mors, General Manager of
Polpharma Biologics selected Box Enterprise Plus for the full suite of Content Cloud features, including:
- Box GxP Validation to seamlessly manage both unregulated and regulated content in the cloud. Polpharma Biologics evaluated the benefits of Box GxP for accelerated validation versus incumbent solutions such as Microsoft Sharepoint.
Box Consultingto drive adoption of Box and assist in the roll-out to teams across the enterprise, including Research and Development, Regulatory Affairs, and Quality Assurance.
“The last two years have proven how crucial cross-institutional research and industry partnership are to drug development and manufacturing process,” said
Box first announced GxP Validation in 2018 as an innovative approach for maintaining GxP compliance in the cloud. With today’s announcement, Polpharma Biologics joins a growing list of leading life science and biotechnology organisations leveraging Box to power new ways of working, including AstraZeneca, Amgen, and Allergan. For more on Box for Life Sciences, visit box.com/industries/life-sciences-biotech.
Polpharma Biologics is an international biotechnology company with its integrated operations in
Box (NYSE:BOX) is the leading Content Cloud that enables organizations to accelerate business processes, power workplace collaboration, and protect their most valuable information, all while working with a best-of-breed enterprise IT stack. Founded in 2005, Box simplifies work for leading organizations globally, including AstraZeneca, JLL, and Morgan Stanley. Box is headquartered in